Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: oxycodone immediate-release Clear all
Completed Phase 3 Interventional

A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

NCT06423703
View directory record Official record
Conditions
Acute Pain
Interventions
Cebranopadol, Oxycodone IR, Placebo Only, Placebo
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
Sheffield, Alabama • Little Rock, Arkansas • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 2, 2026, 10:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Abuse Potential Study of PF-00345439

NCT01986283
View directory record Official record
Conditions
Opioid Users
Interventions
Capsule, PF-00345439, oxycodone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 2, 2026, 10:52 AM EDT
Terminated Phase 3 Interventional Results available

Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway

NCT02740114
View directory record Official record
Conditions
Malignant Neoplasms of Female Genital Organs, Gynecologic Cancer
Interventions
Bupivacaine, Liposomal Bupivacaine, Oxycodone, Pill Diary, Symptom Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2021 · Synced Sep 2, 2026, 10:52 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

NCT00364533
View directory record Official record
Conditions
Arthroplasty
Interventions
Tapentadol IR (CG5503), Placebo, Oxycodone HCL IR
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 2, 2026, 10:52 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

NCT00580294
View directory record Official record
Conditions
Pain
Interventions
Oxymorphone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 2, 2026, 10:52 AM EDT
Completed Phase 2 Interventional Results available

Analgesic Efficacy of (MSIR)/Acetaminophen vs. Oxycodone/Acetaminophen (Percocet)

NCT03088826
View directory record Official record
Conditions
Pain Management
Interventions
Morphine Sulfate, Oxycodone, Acetaminophen
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 2, 2026, 10:52 AM EDT
Not listed Phase 2 Interventional

Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain

NCT03564548
View directory record Official record
Conditions
Cancer, Breakthrough Cancer Pain
Interventions
PPP001, Morphine sulfate or Hydromorphone or Oxycodone
Drug
Lead sponsor
Tetra Bio-Pharma
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 2, 2026, 10:52 AM EDT
Withdrawn Phase 4 Interventional

A Study Comparing Recurrent Use of MSIR, Percocet, and Vicodin at Discharge From the ED

NCT03529331
View directory record Official record
Conditions
Pain
Interventions
Morphine Sulfate Immediate Release, Oxycodone/Acetaminophen, Hydrocodone/Acetaminophen
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 2, 2026, 10:52 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints

NCT05846451
View directory record Official record
Conditions
Herbal Interaction
Interventions
Kratom, Oxycodone
Dietary Supplement · Drug
Lead sponsor
Washington State University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 2, 2026, 10:52 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Non-intrusive Detection of Temporary Neurologic Impairment By Opioids

NCT04223609
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone, Placebo, EyeLink 1000 Plus, Oculo-Cognitive Addition test (OCAT), VT3mini - Eye Tracking Technology for OEMs
Drug · Device · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 59 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 2, 2026, 10:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prescription Opioid Effects in Abusers Versus Non-Abusers

NCT00158184
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
oxycodone 15 mg, oxycodone 30 mg, Placebo 0 mg
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Sep 2, 2026, 10:52 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia

NCT05988710
View directory record Official record
Conditions
Analgesia, Abuse Opioids, Pain
Interventions
Buccal Buprenorphine 300 mcg, Buccal Buprenorphine 600 mcg, Buccal Buprenorphine 900 mcg, Buccal Placebo, Oral Placebo, Oral immediate-release oxycodone 10mg, Buccal Buprenorphine 450mcg
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 2, 2026, 10:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans

NCT01500317
View directory record Official record
Conditions
Effects of 2 Mu-opiates on Gastrointestinal Transit
Interventions
Tapentadol, Oxycodone, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Sep 2, 2026, 10:52 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study Investigating the nCAP Signal Relief Patch in Subjects Undergoing Primary Hip or Knee Replacement Surgery

NCT05252858
View directory record Official record
Conditions
Opioid Use, Pain, Post Operative
Interventions
nCAP Signal Relief Patch, Standard of Care
Device · Other
Lead sponsor
Jacques E. Chelly
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 2, 2026, 10:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain

NCT00463047
View directory record Official record
Conditions
Chronic Pain
Interventions
Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Sep 2, 2026, 10:52 AM EDT
Completed Phase 3 Interventional Results available

NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain

NCT00986180
View directory record Official record
Conditions
Pain, Back Pain, Low Back Pain, Back Pain With Radiation
Interventions
NUCYNTA, Oxycodone IR
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
74
States / cities
Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 71 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Sep 2, 2026, 10:52 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults

NCT03137030
View directory record Official record
Conditions
Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions
GRT7014 - Abuse Deterrend Tablet, Norco 5Mg-325Mg Tablet
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 2, 2026, 10:52 AM EDT
Terminated Phase 4 Interventional Results available

Open-Label Trial Comparing Oxycodone Medications

NCT01162304
View directory record Official record
Conditions
Chronic Pain
Interventions
Extended Release Oxycodone, Immediate Release Oxycodone
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Sep 2, 2026, 10:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg Tablets

NCT00853320
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone hydrochloride tablet 15 mg, Roxicodone™ tablet 15 mg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Sep 2, 2026, 10:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets

NCT00853736
View directory record Official record
Conditions
Healthy
Interventions
Roxicodone™ tablet 30 mg, Oxycodone hydrochloride tablet 30 mg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Sep 2, 2026, 10:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nasal Human Abuse Potential of PTI-821

NCT03475862
View directory record Official record
Conditions
Opioid Abuse Nondependent
Interventions
PTI-821 capsule Manipulated, PTI-821 Non-manipulated, OxyContin, Placebo, Oxycodone
Drug · Other
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 2, 2026, 10:52 AM EDT
Terminated Phase 3 Interventional Results available

Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015

NCT01125917
View directory record Official record
Conditions
Back Pain Lower Back Chronic
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
84
States / cities
Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 2, 2026, 10:52 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults

NCT03137017
View directory record Official record
Conditions
Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions
Norco 5Mg-325Mg Tablet, GRT7014 - Abuse Deterrent Tablet
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 2, 2026, 10:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)

NCT05090280
View directory record Official record
Conditions
Pharmacokinetics
Interventions
PF614 solution, Naltrexone Hydrochloride, Nafamostat Mesylate
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 2, 2026, 10:52 AM EDT